A practical reference on Mod GRF(1-29): what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-11 and is reviewed periodically as new material appears.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
=== Aluminum potassium sulfate and tannic acid (ALTA) === ALTA injection is somewhat different to the other materials because it is a sclerosant (i.e. it is a type causes sclerosis, or hardening of tissue). Therefore, it may be technically classified as a type of sclerotherapy. This injectable material has been used for treatment of grade III to IV prolapsed internal hemorrhoids, where it gives effects similar to hemorrhoidectomy. It has also been used for treatment of rectal prolapse and rectocele. The material causes a local inflammatory reaction, followed by sclerosis and retraction of tissues. This results in a chronic granulomatous inflammatory process and persistent fibrosis. When used to treat rectal prolapse or mucosal prolapse, it is injected into a wider area (not just into the hemorrhoid cushions, but also into parts of the rectal mucosa), leading to thickening and toughening of the anal canal and rectal wall. This has been shown to increase the maximal resting pressure of the anal canal. Therefore, the result is thought to be similar to other injectable bulking agents, although it is claimed that there is no risk of dissipation and no need for repeated procedures. ALTA has the advantage that it may be used to treat related anorectal conditions which would be contraindications for other injectable bulking agents.
=== Anxiety disorders === Panic disorder with or without agoraphobia. Clonazepam has also been found effective in treating other anxiety disorders, such as social phobia, but this is an off-label use. The effectiveness of clonazepam in the short-term treatment of panic disorder has been demonstrated in controlled clinical trials. Some long-term trials have suggested a benefit of clonazepam for up to three years without the development of tolerance.
The official short title of the bill; A ban on pharmacy benefit managers using spread pricing; A ban on the use of federal funds in Medicaid, the Children's Health Insurance Program (CHIP) and the Affordable Care Act from being used to pay for gender-affirming care for adults and children (the Crenshaw Amendment) starting in 2027; Changes to the Medicaid funding formula to increase benefits for Alaska and Hawaii; An expansion of Pell Grants to cover workforce-training programs (the parliamentarian approved a modified version); Requiring states that use their own funds to offer health insurance for illegal immigrants to pay a higher Medicaid funding; Limitations on the pandemic-era employee retention tax credit; $2 billion allocated for Pentagon military intelligence programs and $500 million allocated for missile development; A policy that would have ended SNAP assistance for some households that are also eligible for other assistance; and A provision to allow mining around the Boundary Waters wilderness.
==== Cumaná ==== On the morning of July 16, 1799, the Pizarro anchored at Cumana, and even those weakened by typhus managed to witness their arrival. Humboldt, eager to immerse himself in the new environment, immediately visited the home of their native guide, disregarding the captain's reminder about the need to present credentials to the Governor first. In the shade of a mimosa tree, surrounded by unfamiliar tropical fragrances and the daily life of their host’s family, Humboldt found the experience more rewarding than any official audience could provide. The town of Cumana, or what remained of it after a devastating earthquake, presented a scene of partial ruin. Governor Don Vicente Emparán, a progressive and scientifically minded official, welcomed the explorers warmly. As head of New Andalusia, then part of the Spanish colony of New Granada, Emparán took pride in introducing Humboldt and Bonpland to local crafts, especially textiles and furniture made from native materials. His appreciation for science ensured that Humboldt and Bonpland received favorable treatment during their South American travels. The natural scenery, with its mist-shrouded mountains, vibrant birds, and luxuriant plant life, left Humboldt and Bonpland exhilarated and overwhelmed by the proliferation of unfamiliar sights, sounds, and smells. The explorers quickly secured a spacious house constructed of local woods, cooled by the breeze through open windows.
More potential nutrients from the grape must (though the bacteria will be competing with the yeast for these) Lower sulfur dioxide and ethanol levels which can otherwise inhibit the LAB Higher fermentation temperatures which are more conducive to LAB growth and an earlier completion of MLF: The optimal temperatures for malolactic fermentation are between 20 and 37 °C (68 and 99 °F), while the process is significantly inhibited at temperatures below 15 °C (59 °F). Wine stored in the barrels in the cellar during the winter following fermentation will often have a very prolonged malolactic fermentation due to the cool cellar temperatures. Early completion of malolactic fermentation means the winemaker can make a postfermentation SO2 earlier to protect the wine from oxidation and spoilage microbes (such as Acetobacter). Since sulfur dioxide can inhibit MLF, delaying LAB inoculation till after alcoholic fermentation may mean a delay in sulfur addition till early spring when cellar temperatures warm up enough to encourage the completion of MLF. Less diacetyl production The disadvantages for early inoculation include:
Sources: en.wikipedia.org
An ideal beam-splitter transmits and reflects 50% of the incident radiation. However, as any material has a limited range of optical transmittance, several beam-splitters may be used interchangeably to cover a wide spectral range. In a simple Michelson interferometer, one beam passes twice through the beamsplitter but the other passes through only once. To correct for this, an additional compensator plate of equal thickness is incorporated. For the mid-IR region, the beamsplitter is usually made of KBr with a germanium-based coating that makes it semi-reflective. KBr absorbs strongly at wavelengths beyond 25 μm (400 cm−1), so CsI or KRS-5 are sometimes used to extend the range to about 50 μm (200 cm−1). ZnSe is an alternative where moisture vapour can be a problem, but is limited to about 20 μm (500 cm−1). CaF2 is the usual material for the near-IR, being both harder and less sensitive to moisture than KBr, but cannot be used beyond about 8 μm (1,200 cm−1). Far-IR beamsplitters are mostly based on polymer films, and cover a limited wavelength range.
As mentioned above, G-proteins may terminate their own activation due to their intrinsic GTP→GDP hydrolysis capability. However, this reaction proceeds at a slow rate (≈0.02 times/sec) and, thus, it would take around 50 seconds for any single G-protein to deactivate if other factors did not come into play. Indeed, there are around 30 isoforms of RGS proteins that, when bound to Gα through their GAP domain, accelerate the hydrolysis rate to ≈30 times/sec. This 1500-fold increase in rate allows for the cell to respond to external signals with high speed, as well as spatial resolution due to limited amount of second messenger that can be generated and limited distance a G-protein can diffuse in 0.03 seconds. For the most part, the RGS proteins are promiscuous in their ability to deactivate G-proteins, while which RGS is involved in a given signaling pathway seems more determined by the tissue and GPCR involved than anything else. In addition, RGS proteins have the additional function of increasing the rate of GTP-GDP exchange at GPCRs, (i.e., as a sort of co-GEF) further contributing to the time resolution of GPCR signaling. In addition, the GPCR may be desensitized itself. This can occur as:
==== Dependence ==== Chlordiazepoxide can cause physical dependence and what is known as the benzodiazepine withdrawal syndrome. Withdrawal from chlordiazepoxide or other benzodiazepines often leads to withdrawal symptoms that are similar to those seen with alcohol and barbiturates. The higher the dose and the longer the drug is taken, the risk of experiencing unpleasant withdrawal symptoms becomes greater. Withdrawal symptoms can, however, occur at standard dosages and also after short-term use. Benzodiazepine treatment should be discontinued as soon as possible through a slow and gradual dose-reduction regime. Chlordiazepoxide taken during pregnancy can cause a postnatal benzodiazepine withdrawal syndrome.
== History == The US Food and Drug Administration (FDA) approved sotagliflozin based on evidence from two clinical trials of 11,806 total participants with heart failure or with type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. The trials were conducted at 322 sites in 32 countries (SOLOIST/NCT03521934) and 750 sites in 42 countries (SCORED/NCT03315143) primarily in Europe, South America, and North America. Both trials were used for primary determination of the benefits and side effects of the drug. The benefits and side effects of sotagliflozin were evaluated in the two clinical trials. In both trials, participants were randomly assigned to receive either sotagliflozin or placebo by mouth once a day. Neither the participants nor the healthcare providers knew which treatment was being given until after the trial was completed. The benefit of sotagliflozin was evaluated by measuring the number of predefined events (death from cardiovascular causes, need for hospitalization for heart failure, or urgent medical care visit for heart failure) occurring in the patient population receiving sotagliflozin versus placebo.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.